- Home
- IPHA vs DMF Comparison
IPHA vs DMF Comparison
Compare IPHA & DMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- DMF
- Stock Information
- Founded
- IPHA 1999
- DMF 1988
- Country
- IPHA France
- DMF United States
- Employees
- IPHA N/A
- DMF N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- DMF Finance/Investors Services
- Sector
- IPHA Health Care
- DMF Finance
- Exchange
- IPHA Nasdaq
- DMF Nasdaq
- Market Cap
- IPHA 160.1M
- DMF 152.2M
- IPO Year
- IPHA 2019
- DMF N/A
- Fundamental
- Price
- IPHA $1.98
- DMF $7.17
- Analyst Decision
- IPHA Strong Buy
- DMF
- Analyst Count
- IPHA 1
- DMF 0
- Target Price
- IPHA $11.50
- DMF N/A
- AVG Volume (30 Days)
- IPHA 16.2K
- DMF 60.7K
- Earning Date
- IPHA 03-27-2025
- DMF 01-01-0001
- Dividend Yield
- IPHA N/A
- DMF 2.66%
- EPS Growth
- IPHA N/A
- DMF N/A
- EPS
- IPHA N/A
- DMF 0.15
- Revenue
- IPHA $20,831,349.00
- DMF N/A
- Revenue This Year
- IPHA $220.44
- DMF N/A
- Revenue Next Year
- IPHA $81.85
- DMF N/A
- P/E Ratio
- IPHA N/A
- DMF $45.13
- Revenue Growth
- IPHA N/A
- DMF N/A
- 52 Week Low
- IPHA $1.29
- DMF $5.37
- 52 Week High
- IPHA $3.51
- DMF $6.79
- Technical
- Relative Strength Index (RSI)
- IPHA 48.63
- DMF 45.13
- Support Level
- IPHA $1.77
- DMF $7.13
- Resistance Level
- IPHA $2.03
- DMF $7.38
- Average True Range (ATR)
- IPHA 0.08
- DMF 0.07
- MACD
- IPHA -0.01
- DMF -0.01
- Stochastic Oscillator
- IPHA 65.63
- DMF 12.50
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.